Bio-Techne (TECH) is falling sharply as investors digest the company’s fiscal fourth-quarter 2025 results, which included a swing to a GAAP net loss after recording an $83.1 million impairment tied to the Exosome Diagnostics business that was classified as held-for-sale and divested. The quarter also reflected weaker GAAP profitability, including a GAAP operating loss, which is amplifying concerns about near-term earnings quality and the path back to cleaner reported results.

In the fiscal Q4 2025 release, Bio-Techne reported GAAP EPS of ($0.11) and a GAAP operating loss of ($23.9) million, versus GAAP EPS of $0.25 and GAAP operating income of $45.8 million in the year-ago quarter, with management attributing the deterioration primarily to the Exosome Diagnostics impairment. The Diagnostics and Spatial Biology segment also showed softer top-line performance for the quarter, adding to the negative read-through for the company’s mix and near-term growth visibility.

Even when impairment charges are non-cash, they often reset investor expectations around business quality, portfolio strategy, and segment economics—especially when they coincide with margin pressure. With the stock already under pressure over the past year, a GAAP-loss headline can trigger de-risking and force a re-rating as investors focus on whether adjusted results and end-market demand are strong enough to offset volatility in reported earnings.